sur Carl Zeiss Meditec AG (isin : DE0005313704)
Carl Zeiss Meditec Faces Revenue Decline Amidst Challenging Fiscal Year
Carl Zeiss Meditec AG reported a slight revenue drop for fiscal year 2023/24, registering €2,066.1m compared to the previous year's €2,089.3m. The company's adjusted EBIT was €245.9m, aligning with the forecast of €225-275m. The decline was influenced by a restrictive investment climate and lower consumer confidence globally.
The Ophthalmology Strategic Business Unit saw modest growth, primarily driven by the DORC acquisition, while the Microsurgery unit experienced a 7% decline. EMEA regions witnessed double-digit growth, contrasted by revenue decreases in the Americas and APAC, particularly dampened by high interest rates and health policy uncertainties.
The EBIT margin dropped to 9.4% from 16.7% due to unfavorable product mix and reduced demand. Despite challenges, Carl Zeiss Meditec remains cautiously optimistic about stabilizing EBITA and revenue growth with new product launches and public investment opportunities in 2024/25.
R. P.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Carl Zeiss Meditec AG